3,4-Difluoro-2-methoxyphenylboronic acid, CAS 905583-06-4, is primarily used as a research and pharmaceutical intermediate in organic synthesis. I typically position this compound for medicinal chemistry, discovery research, and the preparation of more complex aromatic molecules rather than as a finished active pharmaceutical ingredient. Its main synthetic value comes from the boronic acid group, which can participate in palladium-catalyzed Suzuki–Miyaura coupling reactions. The fluorine and methoxy substituents also provide a defined electronic and steric pattern for building structure–activity relationship libraries.
This material is an aromatic boronic acid containing a fluorinated methoxy-substituted phenyl ring. The molecular structure includes one boronic acid group, one methoxy group, and two fluorine atoms, giving the building block a molecular weight of approximately 187 g/mol. Its chemical identifier is CAS 905583-06-4, which buyers should use together with the full chemical name when requesting quotations or technical documents.
In practical terms, the compound is a functionalized aryl building block. The boronic acid group is the principal reaction handle, while the fluorine atoms and methoxy group remain part of the target molecule after coupling in many synthetic routes. Because the final behavior depends on purity, water content, physical form, and storage history, I recommend treating supplier specifications and analytical confirmation as essential parts of procurement.
The best-established use of arylboronic acids is carbon–carbon bond formation through Suzuki–Miyaura coupling. In a typical reaction, the arylboronic acid is coupled with an aryl or heteroaryl halide in the presence of a suitable palladium catalyst, base, and reaction solvent. This allows chemists to connect the substituted phenyl ring to another aromatic or heteroaromatic fragment.
For medicinal chemistry, this reaction is valuable because it can be adapted to many substrate combinations. The exact catalyst, base, solvent, temperature, and work-up must be developed for the specific reaction, so I do not recommend treating one general procedure as universally applicable. Instead, buyers should evaluate the material according to the intended coupling partner and the required impurity profile.
3,4-Difluoro-2-methoxyphenylboronic acid can serve as an intermediate during the synthesis of candidate molecules and advanced pharmaceutical building blocks. It is not itself a finished medicine, and its use does not establish any therapeutic effect. Its role is to contribute a defined substituted aromatic fragment to a larger molecule that may later undergo additional transformations and testing.
The combination of fluorine and methoxy substitution can be useful when researchers are investigating how electronic properties, lipophilicity, metabolic stability, or molecular conformation change across a compound series. These effects are molecule-dependent, so I describe the building block as a design option rather than a guarantee of improved performance. Final biological properties must be established through the buyer’s own analytical and pharmacological work.
Medicinal chemistry teams often prepare small libraries of related compounds by changing one fragment while retaining other parts of a core structure. This boronic acid can support that workflow when the target series requires a difluoro-methoxyphenyl substituent. After coupling, the resulting products may be further modified through hydrolysis, oxidation, deprotection, amination, or other synthetic operations.
The value of the material in a library program depends on reaction success, available quantities, reproducibility, and analytical documentation. For an exploratory program, a small package may be sufficient, while process development may require repeated lots or larger quantities. I recommend confirming the required scale before selecting a supplier or requesting a fixed delivery schedule.
These applications describe synthetic uses, not approved commercial indications. A buyer should confirm whether the material is intended for research use, non-clinical development, or a regulated manufacturing process. The documentation and quality expectations can differ substantially between those purposes.
If you are looking for more details, kindly visit Maison Chemical.
Suppliers may offer this compound in different package sizes, analytical grades, and documentation levels. For early-stage screening, buyers may request quantities such as 1 g or 10 g, while route development may require a different commercial format. These quantities are examples for planning only and should not be interpreted as standard Maison Chemical package commitments.
Purity is another important selection factor. A buyer may set an internal acceptance criterion of 95% or 98% area purity depending on the route and project stage, but the correct requirement should be agreed with the technical team. I recommend reviewing the certificate of analysis for assay or chromatographic purity, water content where relevant, residual solvents, appearance, and batch identification.
| Item | Why It Matters |
|---|---|
| CAS 905583-06-4 | Confirms the intended chemical identity during sourcing. |
| Approx. 187 g/mol molecular weight | Supports reaction calculations, stoichiometry, and material planning. |
| Purity target such as 95% or 98% | Helps align the material with the buyer’s internal method and project stage. |
| Package quantity, such as 1 g or 10 g | Allows purchasing teams to match the order to screening or development needs. |
I recommend requesting a current certificate of analysis and confirming that the product name, CAS number, batch number, and test results are consistent. Depending on the project, useful analytical records may include proton NMR, carbon NMR, fluorine NMR, mass spectrometry, and chromatographic purity data. No single document should replace the buyer’s own incoming inspection requirements.
The material should be assessed against the planned coupling route rather than selected only by name. Important questions include whether the target reaction is sensitive to water, whether boronic acid oxidation could affect performance, and whether the product contains impurities that interfere with purification. A qualified supplier should be able to discuss available batch data without claiming that one batch will perform identically in every reaction system.
For repeated pharmaceutical research programs, supply continuity can be as important as the initial price. I suggest confirming available inventory, manufacturing lead time, packaging, storage recommendations, export documentation, and the process for handling repeat orders. If a project is moving toward scale-up, buyers should also ask whether future batches can be produced against an agreed specification.
At Maison Chemical, I support B2B buyers by focusing on clear product identification, practical quotation communication, and documentation appropriate to the project stage. We can discuss the required CAS number, target quantity, purity expectation, packaging preference, destination country, and intended research or development use before confirming a supply proposal. This helps reduce the risk of quoting a material that does not match the buyer’s route or quality requirements.
Our role as a manufacturer, supplier, and exporter of pharmaceutical intermediates is to provide a commercially useful route from technical inquiry to delivery planning. Product availability, lead time, minimum order quantity, and analytical documentation should be confirmed for each inquiry rather than assumed. We also encourage buyers to share any special requirements, including non-standard packaging, additional testing, or repeat-lot planning.
In direct answer, 3,4-Difluoro-2-methoxyphenylboronic acid CAS 905583-06-4 is used mainly to construct more complex aromatic molecules, especially through Suzuki–Miyaura cross-coupling. Its most relevant B2B applications are pharmaceutical intermediate development, medicinal chemistry, custom synthesis, and research library production. The compound is valuable as a defined building block, but its suitability depends on the specific reaction and the buyer’s quality requirements.
As a next step, I recommend preparing the required quantity, purity target, delivery location, intended application, and documentation needs before requesting a quotation. Maison Chemical can then review the inquiry and confirm available specifications, packaging, lead time, and export support. Contact us with your project requirements to begin a technically aligned supply discussion.
If you are looking for more details, kindly visit 3,4-Difluoro-2-methoxyphenylboronic acid CAS 905583-06-4.